Characterization of the Efficacy of Furosemide Depending on Albumin Function
NCT ID: NCT04972617
Last Updated: 2022-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2022-05-17
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Furosemide Stress Test for the Prediction of Acute Kidney Injury Severity in Acute Heart Failure Patients
NCT04464811
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
NCT04986137
Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease
NCT06750575
Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients
NCT05963126
The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury
NCT01275729
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.
In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
observational group
In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient.
The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period.
In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined.
albumin function analysis (ABIC)
After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
albumin function analysis (ABIC)
After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Attending intensive care physician intends to prescribe IV furosemide to increase urine output
* Arterial (central venous if applicable) and urinary catheter in situ
Exclusion Criteria
* Patients who received intravenous or oral diuretics (including mannitol) in the 6 hours prior to study enrolment
* Patients who have received other medications (e.g. fludrocortisone) known to affect renal sodium or water excretion in the 24 hours prior to study entry
* Patients with uncontrolled hyperglycaemia (plasma glucose \>10mmol/L).
* Patients who were receiving renal replacement therapy prior to the start of the study
* Patients with obstructive uropathy, macroscopic haematuria or intra-abdominal hypertension (\>20mmHg)
* Age \< 18 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rostock
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gerd Klinkmann
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steffen Mitzner, MD, PhD
Role: STUDY_DIRECTOR
University Hospital Rostock
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Rostock
Rostock, Mecklenburg-Vorpommern, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Albumin - Furosemid
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.